Dr. Doogan is a seasoned drug development executive and life sciences investor with more than 30 years experience in the global pharmaceutical industry. He joined Pfizer in 1982, where he held a number of senior positions in R&D in the USA, UK and Japan. Dr. Doogan was the clinical development head for what was to become ZOLOFT, an important antidepressant and one of the top selling products in the world. He retired from Pfizer in 2007 as the Senior VP Head of World Drug Development. Subsequently Dr. Doogan was Head of R&D at Amarin where, along with the CEO, he raised $100m to fund the reorganization and portfolio realignment leading to completion of a Phase III program and NDA approval for Vascepa (icosapent ethyl) for elevated triglycerides. During his career Dr. Doogan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the Boards of several biotechnology companies.

Dr. Doogan retired in December 2021.